Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Terminal complement inhibition is the standard of care for atypical hemolytic uremic syndrome (aHUS). The optimal duration of complement inhibition is unknown, although indefinite therapy is common. Here, we present the outcomes of a physician-directed eculizumab discontinuation and monitoring proto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Chaturvedi, Shruti, Dhaliwal, Noor, Hussain, Sarah, Dane, Kathryn, Upreti, Harshvardhan, Braunstein, Evan M., Yuan, Xuan, Sperati, C. John, Moliterno, Alison R., Brodsky, Robert A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2021
Schlagworte:
Thrombosis and Hemostasis
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948299/
https://ncbi.nlm.nih.gov/pubmed/33683339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003175
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge